Semma receives JDRF investment

Cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.) said it received an undisclosed investment from the JDRF T1D Fund. Semma CEO Robert Millman told BioCentury that the investment, which took the form of a convertible note, is part of a planned series B round of undetermined size. The company expects to raise the round in 3Q17.

JDRF launched the T1D fund in January, when it said it had raised $42 million toward its $80 million target. Semma is its third investment, after artificial pancreas company Bigfoot BioMedical Inc. (Milpitas, Calif.) and glucose sensor developer GluSense Ltd. (Rehovot, Israel) (see BioCentury, Jan. 27)...